| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 14 | 2024 | 464 | 2.460 |
Why?
|
| Tissue Extracts | 6 | 2023 | 48 | 1.690 |
Why?
|
| Ipilimumab | 13 | 2024 | 749 | 1.620 |
Why?
|
| CTLA-4 Antigen | 13 | 2021 | 665 | 1.450 |
Why?
|
| Prostatic Neoplasms | 16 | 2024 | 5938 | 1.320 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 727 | 1.100 |
Why?
|
| Myocarditis | 2 | 2024 | 197 | 0.980 |
Why?
|
| Immunotherapy | 16 | 2024 | 3481 | 0.950 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2020 | 1313 | 0.890 |
Why?
|
| Myositis | 1 | 2024 | 89 | 0.890 |
Why?
|
| Abiraterone Acetate | 5 | 2024 | 84 | 0.700 |
Why?
|
| Antibodies, Monoclonal | 10 | 2023 | 4452 | 0.690 |
Why?
|
| Immunotherapy, Active | 1 | 2019 | 47 | 0.660 |
Why?
|
| Tumor Microenvironment | 12 | 2023 | 2981 | 0.640 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2024 | 1658 | 0.640 |
Why?
|
| Neutrophils | 1 | 2021 | 845 | 0.570 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2024 | 608 | 0.570 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 489 | 0.500 |
Why?
|
| B7-1 Antigen | 3 | 2005 | 90 | 0.490 |
Why?
|
| Clonal Evolution | 1 | 2016 | 254 | 0.480 |
Why?
|
| Immunomodulation | 1 | 2016 | 255 | 0.470 |
Why?
|
| Androgen Antagonists | 5 | 2024 | 429 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 16270 | 0.440 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2019 | 592 | 0.410 |
Why?
|
| Biomarkers, Tumor | 9 | 2024 | 10627 | 0.400 |
Why?
|
| Colitis | 3 | 2019 | 338 | 0.390 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 14506 | 0.380 |
Why?
|
| B7-H1 Antigen | 6 | 2023 | 1057 | 0.360 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 111 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2379 | 0.340 |
Why?
|
| Male | 41 | 2024 | 127630 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2019 | 1069 | 0.330 |
Why?
|
| Phenylthiohydantoin | 2 | 2022 | 105 | 0.300 |
Why?
|
| B7 Antigens | 2 | 2019 | 85 | 0.300 |
Why?
|
| Antigens, CD | 5 | 2010 | 1410 | 0.300 |
Why?
|
| Neoplasms | 10 | 2024 | 15710 | 0.290 |
Why?
|
| Lymphocyte Activation | 6 | 2021 | 1698 | 0.280 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2005 | 203 | 0.280 |
Why?
|
| Receptors, IgG | 2 | 2024 | 112 | 0.270 |
Why?
|
| Humans | 55 | 2024 | 270843 | 0.270 |
Why?
|
| Prednisone | 3 | 2024 | 997 | 0.270 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2019 | 717 | 0.270 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3836 | 0.260 |
Why?
|
| T-Lymphocytes | 8 | 2017 | 3955 | 0.250 |
Why?
|
| Th1 Cells | 3 | 2021 | 259 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 7908 | 0.220 |
Why?
|
| Blood Proteins | 1 | 2004 | 297 | 0.210 |
Why?
|
| Middle Aged | 21 | 2024 | 89535 | 0.200 |
Why?
|
| Hypophysitis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Toxicity Tests | 1 | 2021 | 53 | 0.190 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 53 | 0.190 |
Why?
|
| Kallikreins | 1 | 2021 | 87 | 0.190 |
Why?
|
| Aged | 19 | 2024 | 72902 | 0.190 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 50 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 1007 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 524 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 707 | 0.180 |
Why?
|
| Taxoids | 2 | 2024 | 994 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2021 | 111 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 3 | 2019 | 770 | 0.180 |
Why?
|
| Radium | 1 | 2021 | 98 | 0.170 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.170 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2019 | 19 | 0.170 |
Why?
|
| Cell Lineage | 2 | 2019 | 705 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2004 | 846 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2021 | 208 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 100 | 0.170 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 377 | 0.170 |
Why?
|
| Bone Neoplasms | 3 | 2021 | 2652 | 0.170 |
Why?
|
| Autoantibodies | 3 | 2019 | 595 | 0.160 |
Why?
|
| Prostatectomy | 2 | 2021 | 1004 | 0.160 |
Why?
|
| Receptors, Nerve Growth Factor | 3 | 2003 | 33 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 137 | 0.160 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2018 | 36 | 0.160 |
Why?
|
| Thyrotoxicosis | 1 | 2018 | 21 | 0.160 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 215 | 0.160 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 30813 | 0.160 |
Why?
|
| Melanoma | 3 | 2018 | 5445 | 0.150 |
Why?
|
| Peptides | 1 | 2004 | 1504 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 149 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2023 | 34238 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 559 | 0.150 |
Why?
|
| Anilides | 1 | 2020 | 288 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 1030 | 0.150 |
Why?
|
| Cytokines | 5 | 2019 | 2871 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 278 | 0.150 |
Why?
|
| Pneumonia | 2 | 2020 | 761 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1328 | 0.140 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 259 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1430 | 0.140 |
Why?
|
| Gene Expression | 3 | 2021 | 3594 | 0.140 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 893 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2016 | 96 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 259 | 0.130 |
Why?
|
| Radiography, Interventional | 1 | 2018 | 316 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2016 | 97 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2022 | 1059 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2021 | 9487 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 836 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 148 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 200 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2016 | 546 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1335 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 2 | 2017 | 257 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 2868 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 314 | 0.120 |
Why?
|
| Animals | 21 | 2024 | 61014 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3931 | 0.120 |
Why?
|
| Gene Products, gag | 1 | 2013 | 36 | 0.120 |
Why?
|
| Mice | 17 | 2024 | 35331 | 0.110 |
Why?
|
| Immunity | 1 | 2016 | 359 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 679 | 0.110 |
Why?
|
| Endogenous Retroviruses | 1 | 2013 | 42 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2016 | 1163 | 0.110 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2013 | 109 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10257 | 0.110 |
Why?
|
| RNA | 2 | 2021 | 1030 | 0.110 |
Why?
|
| Pyridines | 1 | 2020 | 1291 | 0.110 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 198 | 0.110 |
Why?
|
| Biomarkers | 3 | 2022 | 5176 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 9 | 2018 | 7173 | 0.100 |
Why?
|
| Patient Selection | 1 | 2019 | 2117 | 0.100 |
Why?
|
| Nitriles | 3 | 2023 | 938 | 0.100 |
Why?
|
| Immunization, Passive | 1 | 2011 | 176 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3363 | 0.090 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 445 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1891 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1372 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2004 | 418 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 953 | 0.090 |
Why?
|
| Carboplatin | 2 | 2024 | 844 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 2018 | 4245 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14855 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2016 | 12151 | 0.070 |
Why?
|
| Female | 13 | 2024 | 147292 | 0.070 |
Why?
|
| Heterografts | 2 | 2024 | 750 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3294 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2420 | 0.070 |
Why?
|
| Adult | 6 | 2024 | 80709 | 0.070 |
Why?
|
| Heart Failure | 1 | 2021 | 2663 | 0.070 |
Why?
|
| Diarrhea | 2 | 2020 | 690 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2019 | 376 | 0.070 |
Why?
|
| Prognosis | 4 | 2020 | 22249 | 0.070 |
Why?
|
| CD3 Complex | 2 | 2004 | 316 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4462 | 0.070 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2005 | 96 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 5239 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2021 | 39512 | 0.060 |
Why?
|
| Immune System | 2 | 2018 | 283 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2005 | 132 | 0.060 |
Why?
|
| Succinimides | 1 | 2004 | 8 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2005 | 154 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2024 | 27 | 0.060 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2004 | 35 | 0.060 |
Why?
|
| Fluoresceins | 1 | 2004 | 73 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 2560 | 0.060 |
Why?
|
| Fatigue | 2 | 2021 | 1267 | 0.060 |
Why?
|
| Time Factors | 3 | 2021 | 13266 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 183 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 1331 | 0.060 |
Why?
|
| CD40 Antigens | 1 | 2003 | 111 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 232 | 0.050 |
Why?
|
| Benzamides | 2 | 2022 | 1873 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2003 | 204 | 0.050 |
Why?
|
| Cell Division | 2 | 2004 | 2556 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2016 | 2403 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2004 | 882 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 1111 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2004 | 275 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2004 | 408 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2019 | 3074 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 465 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 6460 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 367 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 775 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2019 | 9324 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2021 | 159 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3666 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 15198 | 0.050 |
Why?
|
| Hydrolases | 1 | 2021 | 133 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1533 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 5242 | 0.050 |
Why?
|
| Androstenes | 1 | 2020 | 43 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 165 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 36 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 251 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 697 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5295 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 7429 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 57 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2004 | 1269 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 89 | 0.040 |
Why?
|
| Survival Rate | 3 | 2021 | 12451 | 0.040 |
Why?
|
| Antigens | 1 | 2019 | 297 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 38 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2019 | 160 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2021 | 5670 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 568 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 717 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 147 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 1597 | 0.040 |
Why?
|
| Homeostasis | 1 | 2003 | 947 | 0.040 |
Why?
|
| Clone Cells | 1 | 2019 | 559 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 336 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2003 | 76 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 258 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 707 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 228 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 637 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 867 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 46 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7303 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 1225 | 0.030 |
Why?
|
| Dasatinib | 1 | 2020 | 878 | 0.030 |
Why?
|
| California | 1 | 2016 | 221 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1314 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 847 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 123 | 0.030 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2005 | 5 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 1168 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 2480 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 3518 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 596 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2017 | 2917 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 764 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 987 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 4776 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 749 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2014 | 1237 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1079 | 0.030 |
Why?
|
| Newcastle disease virus | 1 | 2014 | 7 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1638 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2348 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2005 | 5804 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 876 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1142 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 176 | 0.030 |
Why?
|
| Anemia | 1 | 2019 | 730 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 3490 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 174 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 2572 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1462 | 0.030 |
Why?
|
| Indoles | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1067 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 121 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2014 | 261 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 1104 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 683 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 186 | 0.030 |
Why?
|
| Spleen | 2 | 2005 | 692 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 13310 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 4911 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7704 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1937 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6269 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 5362 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 843 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 1653 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 1589 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10093 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6245 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 9010 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 931 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 9067 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2819 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3109 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2005 | 4 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2005 | 73 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 182 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2005 | 66 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 2004 | 20 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1952 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 127 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2003 | 55 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 214 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5113 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 2736 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 353 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2002 | 25 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 1009 | 0.010 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2002 | 8 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 29 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4071 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2002 | 40 | 0.010 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2002 | 17 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2002 | 33 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2002 | 81 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2003 | 298 | 0.010 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2002 | 40 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6891 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 200 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2002 | 84 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 121 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 2002 | 92 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 193 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 753 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2003 | 902 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 677 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 470 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 221 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 632 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 1350 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 851 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 341 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 22140 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2005 | 1046 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 3062 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 1353 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4281 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 18267 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 2990 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6127 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6224 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 4887 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 3033 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 4168 | 0.010 |
Why?
|